Guillain-Barre Syndrome clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
open to eligible people ages 12-85
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
Orange, California and other locations
Last updated: